Agreement Awarded by DARPA in partnership with the Administration for Strategic Preparedness and Response’s (ASPR) Center of Industrial Base Management and Supply Chain (IBMSC) Kannapolis, NC / College Station, Tx August 28, 2024 – Bright Path Laboratories, Inc., a...
On Rare Disease Day 2024, Bright Path Laboratories shared an amazing step in our commitment to rare diseases. Bright Path successfully completed the development of Amlexanox as a potential treatment for WOREE Syndrome, a devastating rare disease that affects children...
KANNAPOLIS, N.C., Dec. 13, 2023 /PRNewswire/ -- Bright Path Laboratories, a US-based advanced drug development and manufacturing company is proud to announce their contribution to solving drug shortages for the domestic development and manufacturing of two critical...
Our nation's over-dependence on foreign pharmaceutical production has left America vulnerable. The Covid-19 pandemic revealed that the U.S. is dangerously exposed to supply chain disruptions. Our limited domestic manufacturing capabilities of lifesaving medicines is a...
Bright Path Labs chosen as a collaborator in a first-ever National Science Foundation Engines Award
Bright Path Labs chosen as a collaborator in a first-ever National Science Foundation Engines AwardBright Path is proud to have been chosen to collaborate with the The Puerto Rico Science, Technology, & Research Trust in a $1M NSF Innovation Engines Development...
Bright Path Labs is proud to announce its admittance to the Green Chemistry and Commerce Council (GC3)! We are eager to learn from and collaborate with leaders in sustainable and green technologies across different sectors. Our technology and approach are deeply...
Supply chain disruption will be with biopharmaceutical companies for the foreseeable future, according to the recent CFO survey, Supply Chain Resilience, by BDO. A separate report by Catalent, Allogeneic and Autologous Cell Therapies Report 2022, agrees, saying,...
Tony Quinones, CEO of Bright Path Laboratories, discusses the latest on the omicron variant and Covid vaccines with Bryan Curtis and Paul Allen on Bloomberg Daybreak Asia.